$MRKR
Marker Therapeutics, Inc.

2022 Q3 Form 10-Q Financial Statement

#000141057822002292 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $3.950M $790.5K $964.3K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.678M $3.515M $3.733M
YoY Change 13.55% -1.24% 18.89%
% of Gross Profit
Research & Development $7.291M $6.555M $7.026M
YoY Change 7.47% -10.81% 24.51%
% of Gross Profit
Depreciation & Amortization $800.0K $600.0K $576.3K
YoY Change 33.33% 20.0% 14.64%
% of Gross Profit
Operating Expenses $10.97M $10.07M $10.76M
YoY Change 9.43% -7.69% 22.53%
Operating Profit -$7.019M -$9.280M -$9.795M
YoY Change -29.97% -14.93% 11.54%
Interest Expense $99.75K $35.79K $3.120K
YoY Change 12526.58% 1391.25%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$6.920M -$9.244M -$9.911M
YoY Change -44.33% -15.24% 12.88%
Income Tax
% Of Pretax Income
Net Earnings -$6.920M -$9.244M -$9.911M
YoY Change -44.33% -15.24% 12.88%
Net Earnings / Revenue -175.2% -1169.4% -1027.72%
Basic Earnings Per Share -$0.08 -$0.11 -$0.12
Diluted Earnings Per Share -$0.08 -$0.11 -$0.12
COMMON SHARES
Basic Shares Outstanding 83.60M 83.59M 83.11M
Diluted Shares Outstanding 83.60M 83.59M 83.11M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $18.08M $25.82M $28.64M
YoY Change -62.89% -54.87% -55.61%
Cash & Equivalents $18.10M $25.80M $28.64M
Short-Term Investments
Other Short-Term Assets $2.666M $2.827M $2.378M
YoY Change -1.32% 0.89% 21.33%
Inventory
Prepaid Expenses $2.666M $2.827M $2.196M
Receivables
Other Receivables $1.681M $627.6K $2.185K
Total Short-Term Assets $22.42M $29.28M $31.02M
YoY Change -56.38% -51.23% -54.03%
LONG-TERM ASSETS
Property, Plant & Equipment $13.06M $13.74M $14.37M
YoY Change 25.01% 35.93% 39.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $18.69M $23.04M $23.94M
YoY Change -8.97% 12.7% 14.59%
TOTAL ASSETS
Total Short-Term Assets $22.42M $29.28M $31.02M
Total Long-Term Assets $18.69M $23.04M $23.94M
Total Assets $41.11M $52.32M $54.96M
YoY Change -42.85% -34.98% -37.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.021M $1.767M $5.016M
YoY Change -13.11% -13.47% 165.68%
Accrued Expenses $3.498M $3.044M $2.276M
YoY Change 30.85% 26.39% 22.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.29M $13.47M $8.215M
YoY Change 37.19% 138.07% 98.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.226M $10.82M $11.04M
YoY Change -36.79% -6.47% -5.84%
Total Long-Term Liabilities $7.226M $10.82M $11.04M
YoY Change -36.79% -6.47% -5.84%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.29M $13.47M $8.215M
Total Long-Term Liabilities $7.226M $10.82M $11.04M
Total Liabilities $18.51M $24.29M $19.25M
YoY Change -5.82% 41.01% 21.32%
SHAREHOLDERS EQUITY
Retained Earnings -$424.2M -$417.3M -$408.0M
YoY Change 9.23% 11.0% 11.78%
Common Stock $83.60K $83.60K $83.45K
YoY Change 0.63% 0.63% 0.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.60M $28.03M $35.71M
YoY Change
Total Liabilities & Shareholders Equity $41.11M $52.32M $54.96M
YoY Change -42.85% -34.98% -37.81%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$6.920M -$9.244M -$9.911M
YoY Change -44.33% -15.24% 12.88%
Depreciation, Depletion And Amortization $800.0K $600.0K $576.3K
YoY Change 33.33% 20.0% 14.64%
Cash From Operating Activities -$7.646M -$794.7K -$12.23M
YoY Change 1.46% -86.36% 50.94%
INVESTING ACTIVITIES
Capital Expenditures -$99.36K -$2.266M -$2.452M
YoY Change -89.86% 66.51% 457.32%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$99.36K -$2.266M -$2.452M
YoY Change -89.86% 66.51% 75.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 63.57K 0.000
YoY Change -161.04% -100.0%
NET CHANGE
Cash From Operating Activities -7.646M -794.7K -12.23M
Cash From Investing Activities -99.36K -2.266M -2.452M
Cash From Financing Activities 0.000 63.57K 0.000
Net Change In Cash -7.745M -2.997M 28.80M
YoY Change -9.05% -58.89% -33.26%
FREE CASH FLOW
Cash From Operating Activities -$7.646M -$794.7K -$12.23M
Capital Expenditures -$99.36K -$2.266M -$2.452M
Free Cash Flow -$7.547M $1.472M -$9.774M
YoY Change 15.12% -132.96% 27.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83592043
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83030470
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83351184
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69823729
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83592043
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83030470
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
83351184
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69823729
dei Entity Central Index Key
EntityCentralIndexKey
0001094038
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83100000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83600000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37939
dei Entity Registrant Name
EntityRegistrantName
MARKER THERAPEUTICS, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-4497941
dei Entity Address Address Line1
EntityAddressAddressLine1
3200 Southwest Freeway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2500
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77027
dei City Area Code
CityAreaCode
713
dei Local Phone Number
LocalPhoneNumber
400-6400
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
MRKR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
83599187
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25821708
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42351145
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1146186
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2826699
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2484634
CY2022Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
627629
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
237
CY2022Q2 us-gaap Assets Current
AssetsCurrent
29276036
CY2021Q4 us-gaap Assets Current
AssetsCurrent
45982202
CY2022Q2 mrkr Property Plant And Equipment Other Than Construction In Progress
PropertyPlantAndEquipmentOtherThanConstructionInProgress
13740158
CY2021Q4 mrkr Property Plant And Equipment Other Than Construction In Progress
PropertyPlantAndEquipmentOtherThanConstructionInProgress
10096861
CY2022Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
0
CY2021Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2225610
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9303544
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9830461
CY2022Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
23043702
CY2021Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
22152932
CY2022Q2 us-gaap Assets
Assets
52319738
CY2021Q4 us-gaap Assets
Assets
68135134
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4735251
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11134913
CY2022Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
8000000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
0
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
738389
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
620490
CY2022Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1146186
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
13473640
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12901589
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10819825
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11247950
CY2022Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
10819825
CY2021Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
11247950
CY2022Q2 us-gaap Liabilities
Liabilities
24293465
CY2021Q4 us-gaap Liabilities
Liabilities
24149539
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83600000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83100000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
83599
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
83079
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
445215725
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
442020871
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-417273051
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-398118355
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
28026273
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
43985595
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
52319738
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68135134
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
790508
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1754830
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6555299
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7350035
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13581365
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12993064
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3515183
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3559150
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7248184
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6697108
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
10070482
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
10909185
us-gaap Operating Expenses
OperatingExpenses
20829549
us-gaap Operating Expenses
OperatingExpenses
19690172
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-9279974
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10909185
us-gaap Operating Income Loss
OperatingIncomeLoss
-19074719
us-gaap Operating Income Loss
OperatingIncomeLoss
-19690172
mrkr Gain Loss Related To Arbitration Settlement
GainLossRelatedToArbitrationSettlement
-118880
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
35786
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2403
us-gaap Investment Income Interest
InvestmentIncomeInterest
38903
us-gaap Investment Income Interest
InvestmentIncomeInterest
3940
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9244188
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10906782
us-gaap Net Income Loss
NetIncomeLoss
-19154696
us-gaap Net Income Loss
NetIncomeLoss
-19686232
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83592043
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83030470
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83351184
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69823729
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
35705764
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
63573
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1501124
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9244188
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
28026273
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
43985595
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
63573
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3131801
us-gaap Net Income Loss
NetIncomeLoss
-19154696
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
28026273
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
72494919
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3087
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1652087
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10906782
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
63243311
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
27344573
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3900000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
52552758
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3087
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3029125
us-gaap Net Income Loss
NetIncomeLoss
-19686232
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
63243311
us-gaap Profit Loss
ProfitLoss
-19154696
us-gaap Profit Loss
ProfitLoss
-19686232
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1156113
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1032971
us-gaap Share Based Compensation
ShareBasedCompensation
3131801
us-gaap Share Based Compensation
ShareBasedCompensation
3029125
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
517059
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
504232
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
342065
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
743876
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
627392
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-1000273
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4255034
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
108230
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
8000000
us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
0
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1146186
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-300368
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-130503
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13020768
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14885780
mrkr Payments To Acquire Property Plant And Equipment Excluding Construction In Progress
PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress
1229298
mrkr Payments To Acquire Property Plant And Equipment Excluding Construction In Progress
PaymentsToAcquirePropertyPlantAndEquipmentExcludingConstructionInProgress
842048
mrkr Payments For Construction In Progress
PaymentsForConstructionInProgress
3489130
mrkr Payments For Construction In Progress
PaymentsForConstructionInProgress
958965
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4718428
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1801013
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
63573
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52552758
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3087
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
63573
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52555845
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-17675623
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
35869052
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43497331
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21352382
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25821708
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57221434
mrkr Reclassifications Between Construction In Progress And Fixed Assets
ReclassificationsBetweenConstructionInProgressAndFixedAssets
4089135
mrkr Reclassifications Between Construction In Progress And Fixed Assets
ReclassificationsBetweenConstructionInProgressAndFixedAssets
6789098
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
16128
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
159978
mrkr Change To Right Of Use Assets And Lease Liability Due To Close Out Of Operating Lease
ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease
8897
mrkr Change To Right Of Use Assets And Lease Liability Due To Close Out Of Operating Lease
ChangeToRightOfUseAssetsAndLeaseLiabilityDueToCloseOutOfOperatingLease
0
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">NOTE 1: NATURE OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Marker Therapeutics, Inc., a Delaware corporation (the “Company” or “we”), is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The Company’s MultiTAA T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. </p>
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">NOTE 2: BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The results for the condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2022 or for any future interim period. The condensed consolidated balance sheet at June 30, 2022 has been derived from unaudited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2021 and notes thereto included in the Company’s annual report on Form 10-K filed on March 17, 2022.</p>
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25800000
CY2021Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
13100000
CY2021Q3 mrkr Funds Received From Cprit Grant
FundsReceivedFromCpritGrant
2400000
CY2022Q1 mrkr Minimum Bid Price Of Its Common Stock
MinimumBidPriceOfItsCommonStock
1.00
CY2022Q1 mrkr Threshold Consecutive Business Days For Which Notice Received From Nasdaq For Not Maintaining Minimum Bid Price
ThresholdConsecutiveBusinessDaysForWhichNoticeReceivedFromNasdaqForNotMaintainingMinimumBidPrice
30
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28441000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28291000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
250000
us-gaap Comparability Of Prior Year Financial Data
ComparabilityOfPriorYearFinancialData
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prior Period Reclassification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain reclassifications have been made to reclass certain non-cash capital expenditures on the condensed consolidated statements of cash flows from a cash outflow from investing activity to a non-cash investing activity. The Company has evaluated the materiality of this adjustment and concluded it was not material to the previously issued consolidated financial statements and had no impact to the reported condensed consolidated balance sheets, consolidated statements of operations or net loss per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the six months ended June 30, 2021, this immaterial adjustment had the effect of decreasing net cash used in operating activities and increasing net cash used in investing activities by $1.0 million from what was previously reported.</p>
mrkr Adjustments To Net Cash Provided By Used In Operating Activities And Investing Activities
AdjustmentsToNetCashProvidedByUsedInOperatingActivitiesAndInvestingActivities
1000000.0
CY2021Q3 mrkr Receipt Of Product Development Research Award
ReceiptOfProductDevelopmentResearchAward
13100000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2022Q2 mrkr Grant Income Receivable
GrantIncomeReceivable
600000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-9244188
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-10906782
us-gaap Net Income Loss
NetIncomeLoss
-19154696
us-gaap Net Income Loss
NetIncomeLoss
-19686232
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83592043
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83030470
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
83351184
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69823729
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
17636000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12837000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3896000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2740000
CY2021Q4 mrkr Construction In Progress
ConstructionInProgress
2226000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13740000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12323000
CY2022Q2 us-gaap Depreciation
Depreciation
600000
CY2021Q2 us-gaap Depreciation
Depreciation
500000
us-gaap Depreciation
Depreciation
1200000
us-gaap Depreciation
Depreciation
1000000.0
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11600000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9300000
CY2022Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
425000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
425000
us-gaap Operating Lease Cost
OperatingLeaseCost
850000
us-gaap Operating Lease Cost
OperatingLeaseCost
850000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
11000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
226000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
129000
us-gaap Variable Lease Cost
VariableLeaseCost
405000
us-gaap Variable Lease Cost
VariableLeaseCost
262000
CY2022Q2 us-gaap Lease Cost
LeaseCost
659000
CY2021Q2 us-gaap Lease Cost
LeaseCost
554000
us-gaap Lease Cost
LeaseCost
1266000
us-gaap Lease Cost
LeaseCost
1112000
us-gaap Operating Lease Payments
OperatingLeasePayments
633000
us-gaap Operating Lease Payments
OperatingLeasePayments
477000
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y4M24D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.057
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4735000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11135000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
634000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1542000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1826000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1874000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1775000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6997000
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
14648000
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3090000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
11558000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1767000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5144000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1565000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2055000
CY2022Q2 mrkr Accrued Process Development Expenses Current
AccruedProcessDevelopmentExpensesCurrent
357000
CY2021Q4 mrkr Accrued Process Development Expenses Current
AccruedProcessDevelopmentExpensesCurrent
385000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
491000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
644000
CY2022Q2 mrkr Accrued Technology License Fees
AccruedTechnologyLicenseFees
250000
CY2021Q4 mrkr Accrued Technology License Fees
AccruedTechnologyLicenseFees
250000
CY2021Q4 mrkr Arbitration Settlement Liabilities Current
ArbitrationSettlementLiabilitiesCurrent
2407000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
305000
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
19830000
CY2021Q4 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
4.42
CY2021 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
P1Y8M12D
mrkr Number Of Warrant Expired Or Cancelled
NumberOfWarrantExpiredOrCancelled
1348000
mrkr Class Of Warrant Or Rights Outstanding Expired Or Cancelled Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingExpiredOrCancelledWeightedAverageExercisePrice
3.97
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
18482000
CY2022Q2 mrkr Class Of Warrant Or Rights Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightsOutstandingWeightedAverageExercisePrice
4.45
mrkr Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualLife
P1Y3M18D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.48
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1501000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1652000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3132000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3029000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
6300000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
CY2021Q3 mrkr Receipt Of Product Development Research Award
ReceiptOfProductDevelopmentResearchAward
13100000
CY2021Q4 mrkr Funds Received From Grant
FundsReceivedFromGrant
2400000
mrkr Revenue From Grant Related To Cprit
RevenueFromGrantRelatedToCprit
1800000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2022Q2 mrkr Grant Income Receivable
GrantIncomeReceivable
600000
mrkr Compensation Interest And Attorney Fees
CompensationInterestAndAttorneyFees
2400000
CY2021Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
2400000
CY2021 us-gaap Other Expenses
OtherExpenses
2400000
CY2022Q1 mrkr Legal Proceedings Broker Awarded Additional Interest Amount
LegalProceedingsBrokerAwardedAdditionalInterestAmount
100000
CY2022Q1 mrkr Percentage Of Accrual Of Post Judgment Interest
PercentageOfAccrualOfPostJudgmentInterest
0.0102
CY2022Q1 mrkr Amount Of Accrual Of Post Judgement
AmountOfAccrualOfPostJudgement
2500000
CY2022Q2 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
331000
CY2021Q2 us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
955000
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
1344000
us-gaap Related Party Transaction Expenses From Transactions With Related Party
RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
1457000
CY2022Q2 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
100000
CY2022Q3 mrkr Operational Cost Reduction Percentage
OperationalCostReductionPercentage
23.5
CY2022Q3 mrkr Severance And Termination Costs
SeveranceAndTerminationCosts
700000

Files In Submission

Name View Source Status
0001410578-22-002292-index-headers.html Edgar Link pending
0001410578-22-002292-index.html Edgar Link pending
0001410578-22-002292.txt Edgar Link pending
0001410578-22-002292-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrkr-20220630.xsd Edgar Link pending
mrkr-20220630x10q.htm Edgar Link pending
mrkr-20220630x10q001.jpg Edgar Link pending
mrkr-20220630x10q002.jpg Edgar Link pending
mrkr-20220630xex10d2.htm Edgar Link pending
mrkr-20220630xex31d1.htm Edgar Link pending
mrkr-20220630xex31d2.htm Edgar Link pending
mrkr-20220630xex32d1.htm Edgar Link pending
mrkr-20220630xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
mrkr-20220630_def.xml Edgar Link unprocessable
mrkr-20220630_lab.xml Edgar Link unprocessable
mrkr-20220630_pre.xml Edgar Link unprocessable
mrkr-20220630_cal.xml Edgar Link unprocessable
mrkr-20220630x10q_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable